Behavioral Health Business April 26, 2024
In a significant milestone for the rapidly evolving, and at times tumultuous behavioral digital therapeutics (DTx) industry, the FDA granted 510(k) clearance to a novel therapeutic developed by Curio Digital.
Curio’s eight-week prescription-only digital therapeutic treats mild to moderate postpartum depression in patients ages 22 and older in tandem with clinician-supervised outpatient care.
Postpartum depression affects up to 15% of people who give birth, according to the Cleveland Clinic.
“This is an incredible development for women suffering from postpartum depression who are looking for non-pharmaceutical alternatives given the shortage of trained mental health professionals,” Dr. Alice Domar, a women’s health expert and scientific advisor to Curio, said in a statement.
Princeton, New Jersey-based Curio develops technological, behavioral health...
Today's Sponsors
Today's Sponsor